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We report a case of a female patient with Durie-Salmon stage 3A/ISS stage I IgG kappa multiple myeloma (MM) who
developed encephalopathy after high-dose melphalan and hematopoietic stem cell transplant (HSCT). The most common
etiologies for encephalopathy such as infection, narcotic medications, metabolic-electrolyte disturbance, stroke, and central
nervous system (CNS) hemorrhages were ruled out. The patient recovered from the altered mental status spontaneously. The
possibilities of melphalan-induced encephalopathy versus critical-state delirium versus hypercytokinemia induce encephalopathy
were contemplated.
1.Introduction
Neurological complications associated to hematopoietic
stem cell transplant (HSCT) encompass distinctive entities
which can involve the central nervous system (CNS) and
the peripheral nervous system (PNS). Among the most
commonly described in literature are CNS infections (viral,
fungal, and bacterial), metabolic encephalopathies (elec-
trolytes disturbance, febrile and toxic), vascular adverse
events (ischemic or hemorrhagic), tumor relapse, and
polyradiculoneuropathies [1–3]. Various syndromes are also
seen in close relation to the HSCT setting, as are posterior
reversible encephalopathy syndrome (PRES) and Wernicke’s
encephalopathy (WE) [4, 5].
Identifying precipitating factors is crucial on every
patientwithalteredmentalstatus.Melphalanhasbeenlinked
tosomefatalcasesofencephalopathyinthesettingofchronic
kidney disease (CKD) on hemodialysis, during conditioning
regimen for HSCT [6]. Higher dose of melphalan admin-
istered to hemodialysis patients has been linked to more
adverse neurological events than the renal-adjusted dose
[6, 7].
We present a case of unspeciﬁed encephalopathy after
a high-dose melphalan conditioning regimen followed by
autologous hematopoietic stem cell transplant (Auto-
HSCT). Possible etiologies, evaluation and therapeutic
modalities would be discussed.
2. Case History
60-year-old obese African American female with past med-
ical history of diabetes mellitus type II, hypertension, gout,
vertigo, hyperlipidemia, peripheral neuropathy, and CKD
stage II (glomerular ﬁltration rate of 88mL/min) after MM
diagnosis presented with a left groin mass. Biopsy was
consistent with light-chain- (LC-) restricted plasmacytoma
with associated amyloid deposition. Further workup showed
an IgG kappa serum M-spike of 3.2g/dL and multiple lytic
lesions in bone survey without hypercalcemia or anemia.
B2 microglobulin and albumin were 2.5mg/L and 3.9g/dL,
respectively. Bone marrow aspiration and biopsy showed
25% plasma cells with 13q deletion and 1+ by both cyto-
genetics and ﬂuorescence in situ hybridization (FISH). The
patient was therefore diagnosed as having high-risk Durie-
Salmon stage IIIA with an ISS stage I multiple myeloma.
She receivedinduction therapy with4cyclesoflenalidomide,
bortezomib, and dexamethasone, with a very good partial2 Case Reports in Transplantation
response.Thepatientwasthenevaluatedforautologousstem
cell transplant, and pretransplant workup was remarkable
for CKD stage II, albumin at 3.2g/dL, and a Karnofsky
performance status of 80%. Stem cells were mobilized with
Neupogen, and a total of 6.17mill/kg CD 34 cells were
collected. The patient was then admitted to the hospital
and received high-dose melphalan (200mg/m2), followed by
stem cell infusion.
White blood cell (WBC) nadir occurred on day +6 with
engraftment documented by day +13. The treatment-related
toxicities included grade 3 mucositis and grade 2 diarrhea
which started by day +7 after the Auto-HSCT. Supportive
therapy was provided with pain management, aggressive
electrolyte repletion, and antidiarrheal medications. These
toxicitiesimprovedbyday+11.Onday+12thepatientdevel-
oped slow mentation, which progressed rapidly over the next
few days resulting in poor contact with reality, verbalizing
incomprehensiblesounds,inabilitytofollowcommands,and
responsiveness only to painful stimuli. The Glasgow coma
scale at that time was 10/15, (4 for spontaneous eye opening,
2 for incomprehensible sounds at verbal, and 4 while
withdraws of pain). A brain MRI with and without contrast
was performed and was within normal limits. Characteristic
imaging ﬁndings of PRES were not identiﬁed on MRI [4].
Lumbar puncture for cerebral spinal ﬂuid (CSF) evaluation
was performed and herpes simplex virus, human herpes
virus 6, toxoplasmosis, Cryptococcus, West Nile virus, JC
virus, St. Louis encephalitis, and Eastern equine encephalitis
were ruled out. Cytomegalovirus polymerase chain reaction
(PCR) was positive for less than 250 copies, the same as
in serum. CSF cytology was negative for malignancy. Elec-
troencephalogram (EEG) was consistent with nonspeciﬁc
encephalopathy based on generalized slowing and disorga-
nization without focal features. Over the next 8 days the
patient showed no improvement and was restless, anxious,
and tachypneic. No evidence of cranial nerve deﬁcit or lung
parenchymal disease was observed. All medications with
potential psychotropic eﬀect were discontinued at the onset
of the encephalopathic symptoms. No metabolic abnormali-
ties were identiﬁed, and the patient was started on parenteral
nutrition. Thiamine 100mg IV daily was provided upon
consideration of Wernicke’s encephalopathy. The possibility
of ammonia-induced encephalopathy even with normal liver
function tests (LFTs) was contemplated, but levels returned
<200μM/L. Several factors of distress were evident which
includedasuddenincreaseatWBCevenwhileoﬀNeupogen,
an isolated episode of nonneutropenic fever and evidence
of nonoliguric acute kidney injury (creatinine increased
from baseline of 1mg/dL to a maximum of 1.7mg/dL
for a glomerular ﬁltration rate of 52mL/min.). Systemic
evaluationforinfectiousprocess(viral,fungal,and bacterial)
was also performed repeatedly without an isolated organism
identiﬁed.Empiricalbroad-spectrumantimicrobialcoverage
against opportunistic and most commonly related infectious
process in HSCT patients was administered. The therapy
provided consisted of vancomycin, cefepime, micafungin,
and metronidazole, in descalating fashion upon correlation
of the negative panculture evaluation.
On day +20 the patient suddenly recovered from the
altered mental status without neurologic sequelae. Support-
ive therapy was provided to regain patient performance and
strength. Upon interrogation she denied remembering any
of the events. Her last recollection of event was back to the
day before the mental status changes started. The patient
was discharged home by day +26 of the Auto-HSCT with
improvement of performance status and no metabolic or
neurologic disturbances.
3. Discussion
Neurological complications are common after HSCT. These
vary according to the underlying disease, type of transplant,
and conditioning regimen [1], usually associated with poor
survivalwiththemostcommonetiologiesidentiﬁedinAuto-
HSCTbeingtumorrelapse,andinAllo-HSCTCNSinfection
[1].
Three main etiologies were considered as the responsible
for the idiopathic encephalopathy in our patient after careful
evaluation of the case: delirium, melphalan-induced toxicity,
and hypercytokinemia. Delirium is a well-described cause of
altered mentation after HSCT. It was considered after all the
possible organic etiologies of the altered mental status were
ruled out. A study of the Fred Hutchinson Cancer Research
Center evaluated the risk factors pre- and post-HSCT to be
considered as predictive markers for high-risk patients [8].
The study revealed the factors most commonly identiﬁed
in patients who presented with delirium after transplant
with close attention provided to cognitive, liver, and renal
impairment[8].Aspost-transplantriskfactors,inadequately
control pain led to the delirium severity while opioid
medication was associated to delirium onset [8]. Other
alternatives to overuseopioid medications arerecommended
to prevent delirium onset. Our patient was thought to have
delirium related to opioid and psychotropic medications
after transplant. Supportive therapy was provided, and all
medications were withdrawn immediately with the onset
of symptoms. The expected recovery after 72 hours of all
medicationsdiscontinuedidnotoccurleadingustoconsider
some other etiology as the cause of the encephalopathy.
The infusion of high-dose melphalan led to consider the
drug as the culprit of the acute encephalopathy. Mlephalan
toxicity proﬁle includes CNS depression, decreased con-
sciousness, nausea, vomiting, seizures, and muscle paralysis
at doses of 290mg/m2 [9]. Melphalan exerts its eﬀect bound
to plasma proteins; 40 to 60% is bound to albumin leading
patients with hypoalbuminemia clear the medication faster
[10]. In literature one report by Kergueris et al. showed that
patients with normal renal function could eliminate mel-
phalan less eﬃciently due to large interindividual variation
among patients [11]. No dose adjustment is recommended
at studies of drug pharmacokinetics in patients with early-
stage renal insuﬃciency [10, 11]. In our patient melphalan
dose was not adjusted for renal function. With negative
workup for encephalopathy and taking in consideration the
Kergueris report of unspeciﬁed interindividual variation led
us to consider melphalan as the culprit.Case Reports in Transplantation 3
Hypercytokinemia-induced encephalopathy was de-
scribed in a case report of a patient after high-dose mel-
phalan [12]. This encephalopathy was mainly related to
tumor necrosis factor alpha (TNF-α)e ﬀect at brain
through stimulation of glial cells and through the tumor
necrosis factor receptor 1 (TNFR1) [12, 13]. Endotoxemia
through the TNF-α interaction with the TNFR1 leads
to inﬂammation in brain, with alteration in blood-brain
barrier, upregulation of aquaporin 4 (AQP4-associated
edema), neutrophil inﬁltration, astrocytosis, as well as
apoptotic cellular death through nitric oxide mechanism
[13]. Blood puriﬁcation techniques have been studied as
anticytokine therapy. The most studied techniques are
hemoﬁltration, continuous hemodialysis, and continuous
hemodiaﬁltration to modulate the inﬂammatory response
in septic patients [14]. Some other nonrenal indications for
continuous renal replacement therapy with the intention to
remove inﬂammatory mediators were described in literature
[15]. The combined modality of plasma exchange with
continuous hemodiaﬁltration in the setting of critically ill
patients was also evaluated with documented beneﬁt in
patients with hypercytokinemia [16]. The hemodiaﬁltration
procedure was reevaluated through the use of a poly (methyl
methacrylate) membrane hemoﬁlter in 2010 by Nakamura
et al. with evidence of adequate removal of proinﬂammatory
cytokines from blood stream in critical care patients [17].
Focosi described a case of plasma exchange response in
hypercytokinemia after melphalan conditioning regimen
and HSCT [12]. The plasma exchange would remove
pathogenic endotoxins, protein binding agents, and immune
complexes while replenish coagulation factors or albumin
[16]. It was never considered to order cytokine levels prior
admission and during acute phase of the event, the reason
why this diagnosis was not ruled out in our patient.
The etiology of the encephalopathy was not identiﬁed.
Multiple factors need to be evaluated in the setting of
HSCT when encephalopathy presents. The hypercytokine-
mia hypothesis needs to be evaluated through prospective
clinical trials of patients without and with renal insuﬃ-
ciency after myeloablative conditioning regimens for HSCT.
The evidence at two case reports of encephalopathy after
melphalan conditioning regimen for an Auto-HSCT [6, 12]
in patients with CKD on hemodialysis led to consider the
decreased excretion through kidneys as a possible etiology to
toxic adverse events.
This case collects the available data of patients who
suﬀer an encephalopathy in the setting of Auto-HSCT with
melphalan conditioning regimen. Even when we could not
ﬁnd the etiology of the encephalopathy in our case, we hope
this literature review helps others with similar cases for early
evaluation, identiﬁcation of the etiology, and treatment.
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